Antimicrobial (Higher-Risk): LL-37 Honestly Framed

This is the highest-risk-tier application in the catalogue. The only peptide with a real antimicrobial case is LL-37, the human cathelicidin - a peptide that physically disrupts bacterial membranes and degrades biofilms. The same molecule is also a potent immune alarmin that can flare autoimmune disease in susceptible users. Both halves of that are real. The framing here is honest about both.

This page is for users with a specific antimicrobial intent (chronic-Lyme protocols, SIBO-and-biofilm narratives, treatment-resistant gut infections) who have already worked with a clinician. It is not a general-wellness recommendation. If you don't have a clear infectious target and a screening plan, this isn't the right page.

The shortlist

LL-37 - the load-bearing piece, with the load-bearing risk

• What it is. A 37-amino-acid endogenous antimicrobial peptide derived from cathelicidin (hCAP18). The only cathelicidin in humans. Part of the innate immune system; the same molecule is what your skin and gut produce when challenged.
• Mechanism. Three layers, all real: (1) membrane disruption - the positively-charged peptide is electrostatically attracted to negatively-charged bacterial membranes and forms pores, physically lysing the cell; (2) biofilm degradation - penetrates and disperses extracellular polymer matrix, exposing dormant bacteria inside the biofilm to immune attack; (3) immune chemotaxis - recruits neutrophils, monocytes, and T-cells. The mechanism is well-characterised in vitro and in animal models.
• Evidence framing. Tier: Preclinical for systemic injectable use; Clinical for topical wound-healing indications (venous ulcers). Human systemic-injection RCTs for chronic biofilm infections are absent. Community use is real and tied to functional-medicine clinics; the signal is anecdotal.
• Why this is also high-risk. LL-37 is a damage-and- pathogen alarmin. In autoimmune-prone users, exogenous LL-37 can amplify the same inflammatory signalling that drives psoriasis flares, rosacea, lupus activity, and other autoimmune conditions. The molecule that kills bacteria is also the molecule that calls the immune system in - and an immune system already attacking its own tissue is the last thing you want amplified.
• Protocol pattern. 100 mcg SC daily as a starting dose, titrated up cautiously to 500 mcg–1 mg over weeks if tolerated. The injection itself is notably painful (the peptide is membrane-active on the injection-site tissue too - it doesn't differentiate). Cycle durations are usually 4–8 weeks with washout, not chronic. Not a tolerability profile that suits maintenance use.

Thymosin Alpha-1 - the lower-risk adjunct (not a direct antimicrobial)

• Why it's mentioned here. Tα1 is an immune modulator, not an antimicrobial peptide. It doesn't disrupt bacterial membranes. But for users where the antimicrobial intent is layered on top of an immune-resilience context (post-infection recovery, chronic-fatigue framing, recurrent infections), Tα1 fits the broader picture and runs cleaner than LL-37. See Immune Resilience for the standard Tα1 use.
• What it doesn't do. Treat acute infections. Disperse biofilms. Replace antibiotics. The framing here is "support immune tone while a clinician handles the actual infection," not "I'm using Tα1 instead of getting properly diagnosed."

What's NOT in this stack and why

• BPC-157 oral for "gut bacteria." BPC heals gut lining and reduces inflammation. It's not antimicrobial. The community pattern of pairing oral BPC with LL-37 in SIBO protocols treats them as different mechanisms - BPC for the lining, LL-37 for the organism load. Don't substitute one for the other.
• KPV. Anti-inflammatory derived from alpha-MSH; useful for IBD-pattern gut inflammation per Gut Health, but not antimicrobial.
• Berberine, oregano oil, allicin, monolaurin. Not peptides; out of scope. They're frequently part of the same functional-medicine SIBO protocols where LL-37 shows up. This catalogue doesn't try to compare against them.
• "Antimicrobial peptide" research compounds with limited safety data. Magainins, defensins, novel synthetic AMPs - the research literature is interesting but the human safety data isn't there. Out of scope here.

Mandatory pre-cycle screening

More than any other application in this catalogue, LL-37 has stop-signals that need to be checked before the first dose. Skipping these is how the worst LL-37 outcomes happen.

1. Confirmed autoimmune diagnosis. Psoriasis, lupus (SLE), rosacea, rheumatoid arthritis, MS, Hashimoto's - anything in this category. Do not start LL-37. The mechanism of your autoimmune condition involves the same alarmin pathway LL-37 amplifies. The risk of flare is real and not theoretical.
2. Family history of autoimmune disease. Looser criterion, but enough that cautious users skip LL-37 in favour of a clinical workup if antimicrobial intent is real.
3. Active or recent infection that hasn't been diagnosed. Treat the diagnosis path first. LL-37 against an unknown organism is a broad-spectrum bet without a target.
4. Pregnancy or active immunosuppression. Hard contraindications.
5. Cancer history with active treatment. Immune modulators in this context are a clinical question, not a self-managed one.

Decision guide

1. Do you have a clinically-confirmed antimicrobial target?
   → Yes (chronic Lyme co-infection, treatment-resistant SIBO, etc.) → LL-37 may have a place. Continue with screening below.
   → No → wrong tier. This page is not a general wellness recommendation.
2. Are you autoimmune-prone (personal or family history)?
   → Yes → Skip LL-37. Tα1 may fit the immune-resilience framing instead; see Immune Resilience.
   → No → continue.
3. Are you working with a clinician on the underlying diagnosis?
   → Yes → LL-37 protocol below. Coordinate with the clinician; biofilm-disruption protocols can release endotoxin loads that benefit from supportive care.
   → No → fix that first. Self-managed antimicrobial peptide use without a diagnosis is a bad pattern.
4. Tested athlete?
   → LL-37 is research-chemical-status, falls under WADA S0 catch-all. Not compatible with tested competition. See WADA Testing and Detection.

Representative protocol (the only one)

LL-37 cautious titration

• Week 1: 100 mcg SC daily. Yes, this is a low starting dose and yes, it might do nothing. The point is to surface intolerance early, not to produce a clinical effect on day three.
• Week 2: increase to 250 mcg SC daily if tolerated. Stop and reassess if any of: skin flare, joint pain, persistent injection-site reaction larger than ~2 cm, systemic flu-like symptoms beyond mild "die-off."
• Week 3+: 500 mcg–1 mg SC daily as the maintenance dose, if the titration reached this point cleanly.
• 4–8 week cycles, then washout. Not chronic.
• Reconstitute carefully - LL-37 is fragile and needs strict cold-chain management. See Storage and Handling Best Practices.

Die-off vs autoimmune flare - telling them apart

This distinction is load-bearing. Both feel bad. They mean different things and require different responses:

• Die-off (Herxheimer-pattern). Onset 24–72 hours after a dose increase. Mild flu-like symptoms (headache, low-grade fever, fatigue), tracks the antimicrobial activity. Resolves over 24–72 hours as the released endotoxin load clears. Stay at the current dose, hydrate, support liver. Acceptable.
• Autoimmune flare. Onset can be similar or delayed. Skin involvement (psoriatic patches, malar rash, rosacea-pattern flush). Joint pain in a pattern matching known autoimmune target sites (small joints for RA, large for SpA). Persistent or worsening over days, not resolving. Stop LL-37 immediately. Don't titrate down - discontinue. The risk of a forced-on flare is not worth it.

When in doubt, stop. Restarting from a lower dose is always available; reversing autoimmune activation is not always quick.

What stops people

• Skipping the autoimmune screen. The most consequential failure pattern. LL-37 in undiagnosed autoimmune disease can convert a quiet condition into an active flare. The screening is not optional.
• Treating LL-37 as antibiotics-without-prescription. The biofilm angle is real but the mechanism doesn't replace targeted antibiotic therapy for confirmed infections. A clinician with imaging, cultures, and access to actual antibiotics is the load-bearing piece; LL-37 is adjunct.
• Sourcing matters more than usual. LL-37 is fragile and frequently mis-formulated by grey-market vendors. Underdosed or misfolded LL-37 produces "didn't work" reports rather than "I had a terrible reaction" - which is the worst kind of failure mode (you can't tell the protocol from the source). See Sourcing and Verification.
• Continuous use. Cycle this. Chronic LL-37 amplifies cumulative immune-activation risk without proportional benefit. 4–8 week cycles with washout are the community discipline.
• Combining with other immunomodulators. Stacking LL-37 with Tα1 in the same window adds two immune-system inputs that weren't designed to be co-managed by an at-home protocol. Pick one primary intervention; sequence them, don't stack.

Monitoring

• CBC with differential at baseline and end of cycle. Watch lymphocyte and neutrophil trends - LL-37 affects both.
• hsCRP at baseline and during cycle. Rising hsCRP that doesn't track die-off pattern is an inflammation signal worth pausing on.
• ANA, RF, anti-CCP at baseline if any autoimmune suspicion. Negative pre-cycle baseline is reassuring; positive is a stop-signal regardless of symptoms.
• Symptom journal. Daily 1–10 ratings of joint pain, skin condition, GI symptoms, energy. Distinguishes die-off from flare over the cycle.
• Photographic baseline of skin. Day zero plus weekly. Skin manifestations of autoimmune flare are easy to under-notice if you're not looking; photographs catch it.

Cross-references

• LL-37 peptide page - mechanism, dosing detail, and the antimicrobial-vs-alarmin tension at the molecular level.
• Immune Resilience application - the lower-risk Tα1-led path for users where antimicrobial intent overlaps with immune-tone goals.
• Gut Health application - for the SIBO / IBD context where LL-37 sometimes appears alongside BPC-157 oral and KPV.
• Cycling Strategies - the on/off framework that's load-bearing for higher-risk compounds.
• Sourcing and Verification - particularly load-bearing here because LL-37 is hard to make correctly and easy to misfold.